pocketful logo light
pocketful logo light
Laurus Labs Ltd logo

Laurus Labs Ltd

NSE: LAURUSLABS BSE: 540222

₹1816.20

(1.96%)

Wed, 05 Aug 2026, 08:47 am

mtf coin illustrationMTF 5x

Laurus Labs Share Price Live Chart

1 Day

(1.96%)

No Result Found

Summary

  • Market Cap (in Cr)

    73506.87

  • Net Profit (in Cr)

    354.41

  • P/B

    7.40

  • Sector P/E

    33.76

  • P/E

    92.44

  • EV/EBITDA

    31.60

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    7.36

  • ROCE

    8.80

  • Debt/Equity

    0.62

  • EPS (TTM)

    16.46

  • Dividend Yield

    0.09

  • Book Value

    98.18

  • Interest Cover

    2.98

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters27.4927.4927.5927.5927.62
FII25.8226.5226.1625.7025.52
DII13.9712.4311.7311.9411.77
Public32.7133.5634.5134.7735.09
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

80.41

MACD

96.66

50 DMA

1520.21

200 DMA

1167.43

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2453.802075.401945.8016971567.401318.60940.20
Fibonacci2075.401930.851841.5516971552.451463.151318.60
Camarilla1920.261885.571850.8916971781.511746.831712.14

Pivots Level: Classic

R3

+756.80

2453.80

R2

+378.40

2075.40

R1

+248.80

1945.80

1697
1697
Pivot Point
LTP: 1840.60

S1

-129.60

1567.40

S2

-378.40

1318.60

S3

-756.80

940.20

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1761.45

  • 20-EMA

    1681.71

  • 30-EMA

    1624.79

  • 50-EMA

    1537.26

  • 100-EMA

    1388.75

  • 200-EMA

    1212.53

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 Apr 2026board-meetingsAccounts, Quarterly Results, Interim Dividend
30 Apr 2026agm
30 Apr 2026dividend₹1.20 Dividend /Share08 May 2026
23 Jan 2026board-meetingsQuarterly Results
23 Oct 2025dividend₹0.80 Dividend /Share31 Oct 2025
01 Oct 2025dividendInterim Dividend - Rs. - 0.831 Oct 2025
15 May 2025agm
24 Apr 2025dividend₹0.80 Dividend /Share09 May 2025
09 Apr 2025dividendInterim Dividend - Rs. - 0.809 May 2025
24 Oct 2024dividend₹0.40 Dividend /Share06 Nov 2024

Read More

Peer Comparison

Laurus Labs Ltd logo

Laurus Labs Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Laurus Labs Ltd About

Laurus Labs is equipped with an Active Pharma Ingredients (API).(Source : 202503 Annual Report Page No: 188)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2005

Headquarters

CEO

Ravindranath Kancherla

Employees

Contact

Website icon

Website

http://www.lauruslabs.com

Email icon

Email

secretarial@lauruslabs.com; info@lauruslabs.com

Phone icon

Phone

91-891-3061222

Location icon

Location

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Read More

Laurus Labs Ltd Company History

YearHistory
2020
  • Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States.
  • Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
  • Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market.
2021
  • Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance.
  • Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO.
  • Laurus Labs Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children.
  • Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
2022
  • Laurus Labs received purchase orders from a leading Global Life Sciences Company.
2023
  • Laurus Labs received USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment.
  • Laurus Labs signed Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets.
2024
  • Laurus Labs inaugurates new State of the Art R&D facility at IKP Knowledge park.
  • Laurus Labs concludes successful USFDA Audit for API Manufacturing Facility at Hyderabad.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkBuy3690709536.527 Jan 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell3689009536.2327 Jan 2025
ARUN VIJAY NATHANIblockBuy63589430514 Mar 2023
CYBAGE SOFTWARE PRIVATE LIMITEDblockSell63589430514 Mar 2023
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell529337455.414 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy529337455.414 Nov 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell529338476.603 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy529338476.603 Nov 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell284783479.825 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy210010479.825 Oct 2022

Read More

Laurus Labs Ltd News

Laurus Labs Block Trade: ₹16.95 Cr Deal on NSE

Laurus Labs sees a block trade of ~95,224 shares worth ₹16.95 crores on NSE at a price of ₹1780.10 per share.

29 Jul 2026

equity-markets

Laurus Labs NCLT hearing set for Sep 10, 2026

NCLT Amravati schedules next hearing for Laurus Labs' composite scheme on September 10, 2026. The scheme involves demerging LSPL's Unit-1 into Sriam Labs and amalgamating the remainder with the parent.

25 Jul 2026

companies

Laurus Labs Targets 50% CDMO Revenue by FY30

Laurus Labs targets at least 50% of total revenue from CDMO by FY30, with asset turnover ratio above 1.0 and ROCE rising from 19% to 23% over time.

25 Jul 2026

companies

Laurus Labs Q1 FY27 Call Recording Live

Laurus Labs Limited has released the audio recording of its Q1 FY27 results conference call held on July 24, 2026, in compliance with SEBI LODR Regulations 30 and 46.

24 Jul 2026

companies

Laurus Labs Plans Capex Push Across Key Growth Segments

Laurus Labs is on track to increase capital expenditure in human and animal health, peptides, gene therapy, and antibody drug conjugates for FY27 and FY28.

24 Jul 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Laurus Labs Ltd?

    As of 05/08/2026 at 2:17 PM, Laurus Labs Ltd shares are trading at ₹1816.20.

  • 2.What is the market cap. of Laurus Labs Ltd?

    As of 05/08/2026, the market capitalization of Laurus Labs Ltd is ₹98,114.72 crore.

  • 3.When was Laurus Labs Ltd founded?

    Laurus Labs Ltd was founded in 2005.

  • 4.What are the P/E and P/B ratios of Laurus Labs Ltd?

    As of 05/08/2026, Laurus Labs Ltd has a P/E ratio of 89.77 and a P/B ratio of 7.40.

  • 5.How can I buy shares of Laurus Labs Ltd?

    You can buy shares of Laurus Labs Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Laurus Labs Ltd?

    As of March,2026, promoters hold 27.49% in Laurus Labs Ltd, while FIIs, DIIs and public shareholders hold 25.82%, 13.97% and 32.71%, respectively. The government holds 0.00%.

  • 7.Does Laurus Labs Ltd pay dividends?

    Yes, Laurus Labs Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹1.20 Dividend /Share per share.

  • 8.What is the dividend yield of Laurus Labs Ltd?

    As of 05 August, 2026, the dividend yield of Laurus Labs Ltd stands at 0.11%.

  • 9.What are the latest financial results of Laurus Labs Ltd?

    For January,2024, Laurus Labs Ltd reported revenue of ₹5,554.00 crore and a net profit of ₹358.00 crore.

  • 10.What is the Stock symbol of Laurus Labs Ltd?

    LAURUSLABS is the stock symbol of Laurus Labs Ltd.

  • 11.Who is the CEO of Laurus Labs Ltd?

    The CEO of Laurus Labs Ltd is Ravindranath Kancherla.

Open Your Free Demat Account

Enter your phone number